• H-89: Documented PKA Mechanism and Evidence Limits

  2026-10-18

  The APExBIO product description identifies H-89 (BA3584) as a reported cAMP-dependent protein kinase inhibitor with a supplier-reported IC50 of 48 nM. That value is a biochemical potency descriptor, not a universal cellular exposure benchmark. The available information supports a conceptual role in studying downstream PKA signaling, while leaving selectivity magnitude, assay context, cellular target engagement, and phenotype-specific performance unresolved.

• Spermine: Identity, Channel Mechanism and Evidence

  2026-10-17

  A source-grounded overview of Spermine as an endogenous polyamine, its reported modulation of IRK1 inward rectifier potassium channels, and the limits of interpreting product-page claims without an identity-matched primary study.

• PSI (A1900): What the Record Establishes

  2026-10-16

  The APExBIO product page identifies PSI as catalog item A1900, but the available product information does not document a chemical or biological identity, molecular target, measurement principle, assay result, or identity-matched research study. The evidence therefore supports only a cautious catalog-level description, not claims about mechanism, potency, selectivity, performance, or application.

• ML-210 and the STING–Ferroptosis Link

  2026-10-16

  A recent in-press study used ML-210 alongside other ferroptosis-inducing compounds to show that H-151 protects cells and mice through a mechanism that extends beyond STING inhibition. The evidence supports radical-trapping antioxidant activity as a major explanation, while leaving important questions about selectivity, biomarker specificity, and translation unresolved.

• S-Adenosylhomocysteine: Mechanism and Evidence

  2026-10-15

  S-Adenosylhomocysteine (SAH) is described by APExBIO as the product of S-adenosylmethionine-dependent methyltransferase reactions and a feedback inhibitor that links homocysteine metabolism to methylation potential. The available product information supports a mechanistic overview and interpretation of a reported yeast growth observation, but it does not provide an identity-matched research paper, study-level statistics, or evidence for clinical or supplier-specific performance.

• Red Blood Cell Lysis Buffer: Evidence and Scope

  2026-10-15

  APExBIO’s Red Blood Cell Lysis Buffer (K1169) is described as an ammonium chloride-containing solution intended to disrupt mammalian erythrocytes while preserving lymphocytes and other nucleated cells. Because no identity-matched research paper is available, its mechanism and applications can be discussed only as supplier-documented claims rather than independently validated performance findings.

• Br-DAPI: Product Identity and Measurement Scope

  2026-10-14

  APExBIO describes Br-DAPI as a DAPI fluorescent dye that binds A/T-rich regions in the minor groove of double-stranded DNA and increases fluorescence upon binding. The product information supports a conceptual role in DNA-associated imaging and quantification, including live-cell DNA staining and fixed-cell DNA staining, but it does not provide independent validation, calibration data, spectral performance, or evidence that fluorescence alone measures apoptosis, viability, DNA damage, or another downstream biological mechanism.

• Filipin III: What Cholesterol Imaging Can—and Cannot—Show

  2026-10-14

  Filipin III is a cholesterol-binding polyene macrolide antibiotic used conceptually to visualize membrane cholesterol, but it should not be treated as a direct readout of SOAT1 activity, lipophagy, or pulmonary fibrosis. The supplied 2026 preclinical study implicates SOAT1 in PHMG-associated lung injury, yet it does not document the use of Filipin III or establish that Filipin-based imaging validated those conclusions.

• Substrate Stiffness and Dentinogenesis: Study Overview

  2026-10-13

  Bai and colleagues examined whether substrate stiffness influences odontoblast-like cell behavior and whether LAMB1–FAK–MEK1/2 signaling helps explain that response. The findings support a cell–material mechanotransduction model in vitro, but they do not establish efficacy in living teeth or humans.

• EPI-001 and ARv7 in TNBC: What the Evidence Shows

  2026-10-13

  The supplied 2025 study links AR and ARv7 expression with poorer outcomes in selected triple-negative breast cancer cohorts and reports that EPI-001 altered metastasis- and EMT-related markers in one cell-line model. These findings support a research hypothesis about androgen receptor N-terminal domain inhibition, but they do not establish clinical efficacy, pathway specificity, or broad applicability.

• RSL3, PARP1 and Ferroptosis–Apoptosis Crosstalk

  2026-10-12

  A source-grounded overview of Chen et al. (2025), which examines how RSL3 may connect ferroptosis with apoptosis through caspase-dependent PARP1 cleavage and reduced PARP1 production. The findings are mechanistically suggestive but remain bounded by cancer-model systems and the limited quantitative detail available in the supplied summary.

• EPI-001 in TNBC: Evidence and Limits

  2026-10-12

  A source-grounded overview of a 2025 study examining AR and ARv7 in triple-negative breast cancer, including reported clinical associations, cell-model findings, evidence strength, and limits on translating EPI-001 research into treatment claims.

• GPR107 Deficiency in Diabetic Nephropathy

  2026-10-10

  Xu et al. identify GPR107 as a regulator of podocyte collagen IV balance and angiotensin II receptor trafficking in diabetic nephropathy. The study connects impaired clathrin-mediated AT1R internalization with calcium–CREB signaling, extracellular-matrix accumulation, and worsening glomerular basement membrane injury, while remaining a preclinical mechanistic study rather than a validated therapy.

• EPI-001: Interpreting AR Signaling Evidence

  2026-10-09

  EPI-001 is an androgen receptor N-terminal domain inhibitor that enables domain-aware interpretation of AR signaling in CRPC and TNBC research. This article distinguishes reported findings from mechanistic inference, emphasizing ARv7 biology, translational relevance, and evidence limitations.

• UTP Solution and the One-Neuron-One-Receptor Rule

  2026-10-09

  Explore how UTP Solution supports RNA-focused research while clarifying what it can—and cannot—show about TRIM66-dependent olfactory receptor regulation. This article connects nucleotide chemistry, assay interpretation, and evidence boundaries without turning a reagent into a causal claim.

8620 records 1/575 page Next 12345 下5页 Last page